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  Iiwenty－four hour urinary hydroxyproline and urinary hydroxyproline creatinine ratio
was measured without prior dietary restriction in 24 patients with prostatic cancer and 16
paticn亡s with benign pros亡a亡ic hypertr・Phy． B・亡h werc cleva亡ed i1・patients w…th pr・s亡at五c
cancer with active bone metastases compared to the values of prostatic cancer without bone
metastatsis and benign prostatic hypertrophy． ln these cases， the values of urinary hydroxy－
proline creatinine ratio were more reliable． The results show that urinary hydroxyproline
creatinine ratio is a very sensitive indicator of active bone metastases of prostatic cancer
without dietary restriction． ’
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Fig． 2． Standard curve Y＝O．0354X十〇．0830，














Fig． 1． Assay of urinary hydroxyproline
    O，1 O，2 O．3 O．4 O，5
         urine （me）
Fig． 3． Recovery curve． CD： Urine O．D． curve
    involving 15 ptg of hydroxyproline as an
    inner standard reagent． ＠： Urine O．D
    curve． O and （1） are almost parallel
    and difference between O and ＠is
    O．484 （O．D．）， （13．5 ptg） of hydroxypro－
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Fig． 4． Day t．Q day variation of hydroxyproline／creatinine．
       Q－e： Prostatic cancer with active bone metastases
        （not treated or resistant to hormone therapy）
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Fig． 5．．HYdrOxyProline／creatinine are plotted in four different groups．
       Group 1： Benign prostatic hypertrophy as control． Group II：
       Prostatic caricer without bone metastasis． Group III： Prostatic
       eancer with ¢ontrolled bone metastases． Group IV： Prostatic
       cancer with active bone metastases． （not treated or resistant to
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Fig． 6． Hydroxyproline／creatinine are also plotted． Average data of each
    patient are shown． Long bar lines： mean of values． Short bar：













































































Fig． 7． 24－hour hydroxyproline excreation is plotted． Data
    of each patient are treated independly． Long bar：
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’Fig． 8． 24－hour hydroxyproline excretign is plotted． Average
    data of each patient are shown． Long bar： mean
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